◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
Home › All stocks › W › WVE

Wave Life Sciences Ltd (WVE) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-18

Wave Life Sciences Ltd (WVE) operates in the BIOTECHNOLOGY industry and is headquartered in Cambridge, United States with about 317 employees. Its market capitalization is roughly $857 million. In the fiscal year ended 2025-12-31, WVE reported $43M in revenue and ($204M) in net income.

Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health.

Interactive charts & full statements → Open the WVE valuation workbench →

WVE Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
Total Revenue$65M$43M$108M$113M$4M$41M$20M$16M$14M$4M$1M$0M$0M—
Gross Profit$63M$34M$108M$113M$4M$41M($111M)($159M)($120M)($76M)$1M($9M)($2M)($5M)
Gross Margin %96.9%79.3%100.0%100.0%100.0%100.0%-552.2%-997.6%-832.6%-2041.2%73.5%-5858.6%——
Operating Income (EBIT)($217M)($215M)($110M)($68M)($163M)($127M)($153M)($208M)($160M)($103M)($55M)($19M)($5M)($4M)
Operating Margin %-333.8%-504.1%-101.9%-60.0%-4459.3%-310.1%-763.9%-1303.4%-1106.7%-2769.4%-3725.7%-12696.0%——
Net Income($202M)($204M)($97M)($58M)($162M)($122M)($150M)($194M)($147M)($102M)($55M)($19M)($5M)($3M)
Net Margin %-310.8%-478.3%-89.6%-50.8%-4434.7%-298.4%-746.7%-1211.5%-1017.4%-2754.7%-3730.7%-12631.6%——
EBITDA($198M)($196M)($88M)($49M)($153M)($113M)($145M)($201M)($154M)($100M)($55M)($19M)($5M)($3M)
Earnings Per Share (EPS)$-1.09$-1.21$-0.70$-0.54$-2.05$-2.36$-3.82$-5.72$-5.06$-3.85$-2.43$-0.89$-0.25$-0.93
Shares Outstanding (M)202M169M138M106M79M52M39M34M29M27M23M22M—4M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

WVE Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Total Revenue$2M$38M$17M$8M$9M$9M$84M($8M)
Gross Profit$2M$38M$15M$8M$7M$7M$84M($8M)
Gross Margin %100.0%100.0%86.9%100.0%74.8%76.4%100.0%100.0%
Operating Income (EBIT)($74M)($31M)($56M)($56M)($53M)($50M)$23M($64M)
Operating Margin %-3248.3%-81.8%-327.4%-740.7%-606.5%-542.8%27.4%832.7%
Net Income($69M)($26M)($53M)($54M)($50M)($47M)$29M($62M)
Net Margin %-3052.6%-68.2%-308.4%-707.8%-580.2%-510.9%34.9%804.9%
EBITDA($71M)($24M)($51M)($52M)($48M)($45M)$31M($60M)
Earnings Per Share (EPS)$-0.34$-0.13$-0.30$-0.32$-0.31$-0.29$0.17$-0.47
Shares Outstanding (M)202M200M180M168M164M163M172M133M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

WVE Free Cash Flow History

Cash flowTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
Cash from Operations (CFO)($185M)($187M)($151M)($19M)($128M)($89M)($116M)($188M)($23M)($84M)($32M)($13M)($4M)($4M)
Capital Expenditures (CapEx)$1M$1M$1M$1M$1M$1M$1M$4M$10M$19M$6M$2M$1M$0M
Free Cash Flow (FCF)($186M)($188M)($152M)($21M)($129M)($90M)($117M)($192M)($33M)($103M)($37M)($14M)($5M)($4M)
FCF Margin %-286.1%-440.5%-140.3%-18.1%-3539.1%-218.6%-584.4%-1202.2%-227.6%-2768.8%-2521.1%-9463.2%——
Dividends Paid—————————$0M$30M$113M——

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

WVE Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Cash from Operations (CFO)($48M)($60M)($32M)($45M)($46M)($63M)($44M)($46M)
Capital Expenditures (CapEx)$1M$0M$0M$0M$0M$0M$0M$0M
Free Cash Flow (FCF)($49M)($60M)($32M)($45M)($46M)($63M)($44M)($47M)
FCF Margin %-2166.4%-156.9%-186.3%-590.4%-532.4%-688.9%-52.2%610.5%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

WVE Balance Sheet History

Balance sheet2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-31
Total Assets$558M$638M$352M$275M$146M$207M$279M$284M$296M$182M$165M$165M$3M$2M
Cash & Cash Equivalents$368M$602M$302M$200M$88M$151M$184M$147M$175M$143M$150M$161M$1M$0M
Total Liabilities$105M$112M$143M$235M$191M$175M$189M$213M$223M$42M$30M$12M$1M$10M
Total Debt (Short + Long-Term)$4M$8M$8M$7M$5M$5M$4M$3M$2M$0M$0M$0M$1M$10M
Total Shareholders' Equity$454M$526M$210M$40M($45M)$32M$91M$72M$73M$140M$135M$153M$2M($8M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive WVE viewer.

Other Companies in BIOTECHNOLOGY

← WUWAll “W” companiesWVVI →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.